Drugs / Eprenetapopt
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04990778 | Nov 2021 → Mar 2023 | mantle cell lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eprenetapopt | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04990778 ↗ |
| Route | Intravenous | “Given IV” NCT04990778 ↗ |